San Diego, CA, USA, and Munich, Germany – October 21, 2025 – selectION, Inc. (“selectION” or the “Company”), a clinical-stage biopharmaceutical company developing novel treatments for T cell-mediated autoimmune diseases, today announced the successful completion of its phase 1b proof-of-concept trial evaluating si-544, a first-in-class Kv1.3 blocker in patients diagnosed with psoriasis vulgaris.
News & Events
Congratulations to our Scientific Advisor, Dr. Fred Ramsdell, for receiving the 2025 Nobel Prize in Physiology.
His groundbreaking work on T cells and immune regulation has paved the way for innovative immunotherapies, offering new hope to millions of patients living with autoimmune and inflammatory diseases. Dr.…
Read More Meet selectION, Inc. at BIO International Convention in Boston,MA, on June 16th-19th, 2025
SAN DIEGO, May 26, 2025 – Meet selectION’s management team for an update on selectION’s best-in-class Kv1.3 ion channel blocker for the treatment of T-cell mediated autoimmunity while maintaining the…
Read More Meet selectION, Inc. at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 13th-16th, 2025
SAN DIEGO, Dec 9, 2024 – Meet selectION’s management team for an update on selectION’s best-in-class Kv1.3 ion channel blocker for the treatment of T-cell mediated autoimmunity while maintaining the…
Read More selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis
New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity Recruitment…
Read More Meet selectION, Inc. at the BIO International Convention in San Diego, CA, on June 3rd to 6th, 2024
SAN DIEGO, May 20, 2024 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work in atopic dermatitis and…
Read More selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis
si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed 75% of patients receiving si-544 experienced objective clinical improvement, of which 44% achieved clear…
Read More Meet selectION, Inc. at the Global Life Science Partnering & Investor Conference in La Jolla, CA, on February 27th to 29th, 2024
SAN DIEGO, February 1, 2024 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work in atopic dermatitis, psoriasis…
Read More selectION, Inc. to Present Update on Clinical Progress at the 42ndAnnual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024
Best-in-class Kv1.3 blocker has successfully completed a Phase 1b trial in atopic dermatitis patients Pipeline molecule to treat T cell mediated autoimmune diseases – San Diego, CA, USA, and Munich,…
Read More Meet selectION, Inc. at the 42ndAnnual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 8th to 11th, 2024
SAN DIEGO, Dec 11, 2023 – Meet selectION’s management team for an update on selectION’s best-in-class ion channel blockers and the status of the Phase 1b clinical trial in autoimmune…
Read More Site Search
Recent News
- selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of- Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease
- Congratulations to our Scientific Advisor, Dr. Fred Ramsdell, for receiving the 2025 Nobel Prize in Physiology.
- Meet selectION, Inc. at BIO International Convention in Boston,MA, on June 16th-19th, 2025